Angiogenesis inhibitors

(noun)

A substance that inhibits the growth of new blood vessels (angiogenesis). Some angiogenesis inhibitors are a normal part of the body's control, some are administered as drugs, and some come from diet.

Related Terms

Examples of Angiogenesis inhibitors in the following topics:

  • Angiogenesis and Disease

    • It is also a fundamental step in the transition of tumors from a dormant state to a malignant one, leading to the use of angiogenesis inhibitors.
    • Bone marrow cell recruitment also participates in tumor angiogenesis .
    • Angiogenesis is also required for the spread of a tumor, or metastasis.
    • Angiogenesis becomes clearly evident during dysplasia and is critical for further growth.
    • Targeting tumor angiogenesis may be a novel strategy for preventing cancer.

  • Protease Inhibitors

    • Natural protease inhibitors are found in Shiitake mushrooms.
    • Protease inhibitors are short peptide-like molecules that are competitive inhibitors of the enzyme.
    • Saquinavir is the first clinically used peptide-like inhibitor.
    • Some protease inhibitors do not mimic peptides in their structure.
    • It is one of the major drawbacks of protease inhibitors therapy.

  • Nucleotide and Nonnucleotide Reverse Transcriptase Inhibitors

    • The first two inhibitors act on the same principle.
    • Nucleoside and nucleotide inhibitors are also called competitive substrate inhibitors.
    • Non-nucleotide inhibitors are non-competitive inhibitorsof reverse transcriptase.
    • Resistance to the non-nucleotide inhibitors is caused by mutations in the inhibitor binding site of the enzyme.
    • Such mutations prevent the binding of the inhibitor to the enzyme.

  • Lung Cancer

    • The epidermal growth factor receptor (EGFR) regulates cell proliferation, apoptosis, angiogenesis, and tumor invasion.
    • Mutations and amplification of EGFR are common in non-small-cell lung cancer and provide the basis for treatment with EGFR-inhibitors.

  • Overview of Hemostasis

    • When endothelial injury occurs, the endothelial cells stop secretion of coagulation and aggregation inhibitors and instead secrete von Willebrand factor, which causes platelet adherence during the initial formation of a clot.

  • Development of the Heart

    • The development of the circulatory system occurs by the process of vasculogenesis followed by angiogenesis, the sprouting of new vessels from pre-existing ones.
    • Vasculogenesis is the process of blood vessel formation by new production of endothelial cells, in contrast with angiogenesis in which new blood vessels are formed from pre-existing vessels.
    • For example, if a monolayer of endothelial cells begins sprouting to form capillaries, angiogenesis is occurring.
    • These vascular trees are then pruned and extended through angiogenesis.

  • Control of Metabolism Through Enzyme Regulation

    • In noncompetitive allosteric inhibition, inhibitor molecules bind to an enzyme at the allosteric site.
    • However, allosteric inhibitors are not the only molecules that bind to allosteric sites.
    • However, while ATP is an inhibitor, ADP is an allosteric activator.
    • Competitive inhibitors affect the initial rate, but do not affect the maximal rate, whereas noncompetitive inhibitors affect the maximal rate.
    • Allosteric inhibitors modify the active site of the enzyme so that substrate binding is reduced or prevented.

  • Antiviral DNA Synthesis Inhibitors

    • Another type of drug that is a DNA synthesis inhibitor is foscarnet.
    • This inhibitor is active against the viral DNA polymerases at doses much lower than the ones needed to inhibit the human polymerases.
    • Review the mechanism of action for antiviral DNA synthesis inhibitors and recognize the types of these inhibitors

  • Inhibiting Protein Synthesis

    • Protein synthesis inhibitors are substances that disrupt the processes that lead directly to the generation of new proteins in cells.
    • A protein synthesis inhibitor is a substance that stops or slows the growth or proliferation of cells by disrupting the processes that lead directly to the generation of new proteins.
    • In general, protein synthesis inhibitors work at different stages of prokaryotic mRNA translation into proteins like initiation, elongation (including aminoacyl tRNA entry, proofreading, peptidyl transfer, and ribosomal translocation), and termination.

  • Intermolecular Addition Reactions

    • Indeed, free radical polymerization of simple substituted alkenes is so facile that bulk quantities of these compounds must be protected by small amounts of radical inhibitors during storage.
    • These inhibitors, or radical scavengers, may themselves be radicals (e.g. oxygen and galvinoxyl) or compounds that react rapidly with propagating radicals to produce stable radical species that terminate the chain.
    • Inhibitors include quinones, substituted phenols, aryl amines and nitro compounds.